The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | MRD: a valuable tool in CLL
Othman Al-Sawaf, MD, University Hospital of Cologne, Cologne, Germany, highlights the importance of measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL), emphasizing the crucial role that this tool plays in allowing clinicians to better understand disease progression and remissions. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
